| DOPA, dopa | dihydroxyphenylalanine |
|---|---|
| L-DOPA, | L-dopa levodopa, levo-3, 4-dihydroxyphenylalanine |
| PAO | peak acid output; peripheral airway obstruction; plasma amine oxidase; polyamine oxidase; pulmonary ... |
| DDC | L-Dopa De-Carboxylase |
| DOPA | 3,4-Dihydr-Oxy-Phenyl-Alanine |
| (18)F-DOPA | 6-[(18)F]fluoro-L-DOPA |
|---|---|
| L-DOPA | L-Dihydroxphenylalanine |
| 6-FD | 18F]6-fluoro-L-dopa |
| DOPA | 3,4-dihydrophenylalanine |
| DA | DOPA and dopamine |
Nadsonieae
| dopa oxidase | Provisional name given the enzyme(s) catalyzing the formation of melanins from dopa; it now appears that the copper-containing monophenol monooxygenases and/or catechol oxidases are responsible for the oxidation of l-tyrosine to dopa and dopa quinone. (05 Mar 2000) |
|---|
| alpha methyl dopa | <drug> An antihypertensive drug, preferred in pregnant patients. (18 Nov 1997) |
|---|---|
| decarboxylated dopa | <drug> A catecholamine neurotransmitter and hormone (153 D), formed by decarboxylation of dehydroxyphenylalanine (dopa). A precursor of adrenaline and noradrenaline. Pharmacologic action: 1. Precursor of norepinephrine 2. Stimulates dopaminergic, alpha and beta-1 adrenergic receptors: 3. Dopaminergic (1-2 mcg/kg per min): cerebral, renal, and mesenteric vasodilation increase urine output 4. Mixed alpha and beta-1 (2-10 mcg/kg per min): increases cardiac ouput with moderate increase systemic vascular resistance 5. Predominantly alpha (>20 mcg/kg per min): increases systemic vascular resistance Uses: 1. Treat hypotension associated with bradycardia 2. Stimulate cardiac output and urine output Dose: 1. Start infusion at 1-5 mcg/kg per min and titrate to effect. 2. Use the lowest dose that provides the desired hemodynamic improvement. 3. Do not exceed 20 mcg/kg per min. Potential complications: 1. May increase pulmonary pressure and worsen pulmonary congestion. 2. May increase myocardial work without improving coronary blood flow, exacerbating myocardial ischemia 3. Stimulates heart rate and may cause supraventricular or ventricular arrhythmias (15 Mar 2000) |
| dopa | An amino acid derived from the amino acid tyrosine. It is formed as the first intermediate in the production of dopamine, a neurotransmitter. (09 Oct 1997) |
| dopa decarboxylase | <enzyme> One of the aromatic-l-amino-acid decarboxylases, this enzyme is responsible for the conversion of dopa to dopamine. It is of clinical importance in the treatment of parkinson's disease. Registry number: EC 4.1.1.- (12 Dec 1998) |
| DOPA dioxygenase | <enzyme> Key enzyme in betalain biosynthesis pathway of amanita muscaria; genbank y12886 Registry number: EC 1.14.99.- Synonym: dopa-4,5-dioxygenase, doda gene product (26 Jun 1999) |
| dopa quinone | An oxidation product of dopa and an intermediate in the formation of melanin from tyrosine. (05 Mar 2000) |
| dopa reaction | A dark staining observed in fresh tissue sections to which a solution of dopa has been applied, presumably due to the presence of dopa oxidase in the protoplasm of certain cells. Synonym: Bloch's reaction. (05 Mar 2000) |
| dopa-responsive dystonia | A condition successfully treated with drugs. Typically, DRD begins in childhood or adolescence with progressive difficulty in walking and, in some cases, spasticity. Segawa's dystonia is an important variant of DRD. In Segawa's dystonia, the symptoms fluctuate during the day from relative mobility in the morning to increasingly worse disability in the afternoon and evening as well as after exercise. Some scientists feel DRD is not only rare but also rarely diagnosed since it mimics many of the symptoms of cerebral palsy. (12 Dec 1998) |
| Dopa-tyrosine sulfotransferase | <enzyme> Active towards tyrosine and dopa isomers except dl-ortho-tyrosine; isolated from rat liver; genbank u38419 Registry number: EC 2.8.2.- (26 Jun 1999) |
| dystonia, dopa-responsive | A condition successfully treated with drugs. Typically, DRD begins in childhood or adolescence with progressive difficulty in walking and, in some cases, spasticity. Segawa's dystonia is an important variant of DRD. In Segawa's dystonia, the symptoms fluctuate during the day from relative mobility in the morning to increasingly worse disability in the afternoon and evening as well as after exercise. Some scientists feel DRD is not only rare but also rarely diagnosed since it mimics many of the symptoms of cerebral palsy. (12 Dec 1998) |
| l-dopa | <chemical> The naturally occurring form of dopa and the immediate precursor of dopamine. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to dopamine. It is used for the treatment of parkinsonism and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. Pharmacological action: antiparkinson agents, dopamine agents. (12 Dec 1998) |
| L-dopa peroxidase | <enzyme> Found in human erythrocytes associated with catalase Registry number: EC 1.11.- (26 Jun 1999) |
| acetaldehyde oxidase | <enzyme> Acetaldehyde is converted to acetate Registry number: EC 1.2.- (26 Jun 1999) |
| acyl-CoA oxidase | <enzyme> Catalyses stoichiometric conversion of palmitoyl-CoA and o2 into 2-hexadecenoyl-CoA and h2o2; oxidises acyl-CoA's with carbon chain lengths of 4 to 20; most active toward lauroyl-CoA, but not acetyl- or succinyl-CoA Registry number: EC 1.3.3.6 Synonym: fatty acyl CoA oxidase, fatty acyl-coenzyme a oxidase, fatty acid acyl-CoA oxidase, acox, pox1 gene product (26 Jun 1999) |
| adrenaline oxidase | amine oxidase (flavin-containing) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|